# A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Source: https://onco.cc/trials/nct06434597/  
OnCo record `nct06434597` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SPH5030 in colorectal cancer, run by Shanghai Pharmaceuticals Holding Co., Ltd, now recruiting.

## Summary

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. is a phase 2 interventional study registered as NCT06434597 by Shanghai Pharmaceuticals Holding Co., Ltd, with 60 participants planned, started 2024-07-17 and due to reach its primary completion in 2026-12-31. Interventions recorded: SPH5030.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06434597
- Phase: 2
- Setting: A Multicenter, Open, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of SPH5030 Tablets in Subjects With Her2-positive/Mutated Biliary Tract OR Colorectal Cancer.
- Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06434597: https://clinicaltrials.gov/study/NCT06434597

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [GenFleet Therapeutics](https://onco.cc/companies/genfleet/)

---
JSON: https://onco.cc/api/v1/entities/nct06434597.json